Levetiracetam Intravenous Infusion: A Randomized, Placebo‐controlled Safety and Pharmacokinetic Study
- 19 July 2006
- Vol. 47 (7), 1128-1135
- https://doi.org/10.1111/j.1528-1167.2006.00586.x
Abstract
The primary objective of this placebo-controlled study was to evaluate the safety and tolerability of levetiracetam (LEV) administered intravenously (IV) at higher doses and/or at a faster infusion rate than proposed. The secondary objective was to assess LEV pharmacokinetics. Single ascending doses of LEV administered by IV infusion (2,000, 3,000, 4,000 mg over 15 min; 1,500, 2,000, 2,500 mg over 5 min) were evaluated in 48 healthy subjects in a randomized, single-blind, placebo-controlled study. All randomized subjects completed the study. Adverse events reported after IV administration of LEV (<or=4,000 mg infused over 15 min and <or=2,500 mg infused over 5 min) were primarily related to the CNS (dizziness, 52.8%; somnolence, 33.3%; fatigue, 11.1%; headache, 8.3%) and were consistent with the established safety profile for the oral formulation. Safety profiles were similar for each dose level of LEV and for both IV infusion rates, with no clear relation noted between incidence of adverse events and IV dose level or infusion rate. The pharmacokinetics of LEV administered by IV infusion was comparable across all dose groups and infusion rates. Respective geometric means (coefficient of variation) for 4,000 mg administered over 15 min and 2,500 mg infused over 5 min were maximum plasma concentration, 145 (24.6%) and 94.3 (36.2%) mug/ml; area under the plasma concentration-time curve, 1,239 (19.2%) and 585 (9.6%) mug/h/ml; terminal half-life, 8.0 (14.5%) and 7.0 (12.7%) h. LEV administered by IV infusion at dosages and/or infusion rates higher than those proposed was well tolerated in healthy subjects, and the pharmacokinetic profile was consistent with that for LEV administered orally.This publication has 32 references indexed in Scilit:
- Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: A pooled analysis of data from randomized clinical trialsEpilepsy Research, 2005
- The Antiepileptic Drug Levetiracetam Decreases the Inositol 1,4,5-Trisphosphate-Dependent [Ca2+]iIncrease Induced by ATP and Bradykinin in PC12 CellsThe Journal of pharmacology and experimental therapeutics, 2005
- Clinical Pharmacokinetics of LevetiracetamClinical Pharmacokinetics, 2004
- Levetiracetam: Relative Bioavailability and Bioequivalence of a 10% Oral Solution (750 mg) and 750‐mg TabletsThe Journal of Clinical Pharmacology, 2003
- Levetiracetam reduces caffeine-induced Ca2+ transients and epileptiform potentials in hippocampal neuronsNeuroReport, 2003
- Pharmacokinetics of LevetiracetamEpilepsia, 2001
- Safety Profile of LevetiracetamEpilepsia, 2001
- Pharmacokinetics of LevetiracetamEpilepsia, 2001
- Safety Profile of LevetiracetamEpilepsia, 2001
- Multicenter Double‐Blind, Randomized, Placebo‐Controlled Trial of Levetiracetam as Add‐On Therapy in Patients with Refractory Partial SeizuresEpilepsia, 2000